Michael Wesley Milks, MD, identifies clinical scenarios in which non-statin lipid lowering treatments are indicated for ASCVD risk reduction. Dr. Milks also discusses guidelines for management of blood cholesterol and the effectiveness of new medications.
Related Presenters
